Hmm this guy conjectures that Elan may be a good buy now even after that near term runup. Elan has a good pipeline and hoepfully no more PML will be found from those people that took just Tysabri alone. This drug sounds pretty interesting too:
Their Alzheimer's research is a collaboration with Wyeth where they look to use the patient's own immune system to remove beta amyloid plague. This is a second-generation effort that is currently in Phase II.
This sounds like a very interesting drug that could bring in the big bucks for Elan. 400,000 people in the US have MS but some people estimate that 4.5 million people have Alzheimers. Any Tysabri news will make the stock volitile for a while but it may be a good buy going forward. I've put it on my watch list.
No comments:
Post a Comment